STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Hello, everyone, and how are you today? We are muddling along, but the middle of…
Category: pharmalittle
STAT+: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more
Good morning, everyone, and how are you today? We are just fine, thank you, especially…
STAT+: Pharmalittle: UCB selling a Chinese business, Tome layoffs, and more
Happy Monday, Pharmalittle family. Adam Feuerstein here, once again filling in for Ed. I have…
STAT+: Pharmalittle: We’re reading about AstraZeneca threatening the U.K., mpox vaccine distribution, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more
Good morning, Pharmalittle fans! Adam Feuerstein here, filling in for Ed. I drink my morning…
STAT+: Pharmalittle: We’re reading about obesity drugs and suicidal thoughts, a FDA official’s conflicts, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Medicare drug savings, Lilly warning doctors, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: Pharmalittle: We’re reading about an AstraZeneca U.K. vaccine plant, Medicare premiums, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Novartis losing bid to block a generic, pharma deals, and more
Rise and shine, everyone, another busy day is on the way. Our mascots, for instance,…
STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a California bill to restrain PBMs, a U.K. trade group scolding Novo, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Purdue overdose-reversal device, a discontinued Merck trial, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Roche plans for Flatiron, underwhelming Novo Nordisk earnings, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about a canceled Roche trial, low VC biotech funding, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Pharmalittle: We’re reading about MDMA trials, weight loss drug availability, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more
Good morning, and happy Friday. This is Jonathan Wosen, West Coast biotech and life sciences…
STAT+: Pharmalittle: We’re watching positive Zepbound cardiovascular data, a move to take 23andMe private, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed for the…
STAT+: Pharmalittle: We’re watching GLP-1 drug data in Alzheimer’s, a flu shot push for livestock workers, and more
Good morning, folks! The Dean of Pharmalittle University, Ed Silverman, is out on vacation. I…
STAT+: Pharmalittle: We’re reading about the U.K. nixing coverage for a cancer drug, sharing bird flu vaccine data, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a critical video, Roche fast-tracking an obesity pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a thumbs down for an Alzheimer’s drug, Pfizer gene therapy struggles, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Viking obesity drug, Bausch Health’s bankruptcy denial, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a CVS deal with Illinois, a Pfizer hemophilia therapy, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Express Scripts overcharging postal workers, Gilead’s AIDS drug price, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about an FDA rare disease innovation hub, fewer U.S. drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Gilead’s CMO leaving, Novartis hedging on a drug, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Vertex suing HHS over a fertility program, Hawaii losing a PBM suit, and more
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Pharmalittle: We’re reading about Senate aides meeting with Novo Nordisk, private drug prices in Germany, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about a study of Ozempic and dementia, smaller PBMs, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about biopharma layoffs, Purdue bankruptcy talks, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about an FTC report on PBMs, Lilly vs. Novo weight loss study, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Ozempic and an eye condition, a failed Roche cancer drug trial, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a GSK vaccine deal, an Alzheimer’s drug approval, and more
Top of the morning to you, and a fine one it is. The skies are…
STAT+: Pharmalittle: We’re reading about FTC probing Teva patents, a Moderna flu vaccine contract, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more
And so, another working week will soon draw to a close. Not a moment too…